Oligonucleotide-Enabling Technology Pushes Oligos to the Forefront (AAPS PharmSci 360)
Matthew Lauber, senior director—Cell and Gene Therapy, Consumables & Lab Automation, at Waters Corporation highlights how current technologies are enabling oligonucleotide development.
In an exclusive interview with Pharmaceutical Technology®, Matthew Lauber, senior director—Cell and Gene Therapy, Consumables & Lab Automation, Waters Corporation remarks on how current technologies have enabled oligonucleotide (oligo) development to push forward to the forefont.
“Synthetic oligos just so interesting because it is the world in between the biologically produced, recombinantly produced, drugs and those small-molecule drugs that have been produced through traditional synthetic pharma science,” he states.
Much of the work being conducted on oligo drug development has centered around modifications of the oligo molecule, he emphasizes. “Notice that, even in our mRNA [messenger RNA] vaccines, [which gave us] Nobel laureates Karikó and Weissman, one of the big things that unlocked mRNA vaccines was a modified nucleotide,” Lauber notes.
“These are the same things … it's a modification of these things that are our genome code—our transcriptome code— that is giving us our opportunity for a new form of science,” Lauber states.
AAPS PharmSci 360 ran Oct. 22–25 in Orlando, Fl.
View Lauber’s video interviews about oligonucleotide development challenges, the need for new bioanalysis technology, and the oligonucleotide trend.
Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines
April 30th 2024In this episode fo the Drug Solutions Podcast, etherna’s vice-president of Technology and Innovation, Stefaan De Koker, discusses the merits and challenges of using mRNA as the foundation for therapeutics in oncology as well as for vaccines.
Shilpa Medicare Launches ‘Hybrid CDMO’ at DCAT Week 2025
March 17th 2025This model is being positioned by Shilpa as a dual approach that offers comprehensive discovery, clinical, and commercial outsourcing services in addition to commercially ready, “off-the-shelf” novel formulations for b2b licensing.
Drug Solutions Podcast: Applying Appropriate Analytics to Drug Development
March 26th 2024In this episode of the Drug Solutions Podcast, Jan Bekker, Vice President of Business Development, Commercial and Technical Operations at BioCina, discusses the latest analytical tools and their applications in the drug development market.
